Pace Pharmatech Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 03-07-2024
- Paid Up Capital ₹ 5.00 M
as on 03-07-2024
- Company Age 22 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 27.40 M
as on 03-07-2024
- Satisfied Charges ₹ 11.10 M
as on 03-07-2024
- Revenue 29.18%
(FY 2020)
- Profit 166.39%
(FY 2020)
- Ebitda -12.63%
(FY 2020)
- Net Worth 21.86%
(FY 2020)
- Total Assets 27.40%
(FY 2020)
About Pace Pharmatech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹2.74 Cr. The company has closed loans amounting to ₹1.11 Cr, as per Ministry of Corporate Affairs (MCA) records.
Saurabh Agarwal, Sanjay Omprakash, and Ajay Agarwal serve as directors at the Company.
- CIN/LLPIN
U24231MH2001PTC134109
- Company No.
134109
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Dec 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Pace Pharmatech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saurabh Agarwal  | Director | 06-Sep-2018 | Current |
| Sanjay Omprakash | Director | 05-Jul-2004 | Current |
| Ajay Agarwal | Director | 04-Dec-2001 | Current |
Financial Performance and Corporate Structure Insights of Pace Pharmatech.
Pace Pharmatech Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 29.18% increase. The company also saw a substantial improvement in profitability, with a 166.39% increase in profit. The company's net worth Soared by an impressive increase of 21.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pace Pharmatech?
In 2020, Pace Pharmatech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 Jul 2020 | ₹2.50 M | Open |
Others Creation Date: 09 Jul 2019 | ₹1.75 Cr | Open |
Others Creation Date: 31 Jan 2018 | ₹7.00 M | Open |
How Many Employees Work at Pace Pharmatech?
Unlock and access historical data on people associated with Pace Pharmatech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pace Pharmatech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pace Pharmatech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
